Raymond James Financial began coverage on shares of Zymeworks (NYSE:ZYME) in a research report released on Monday, Marketbeat reports. The firm issued an outperform rating and a $18.00 price objective on the stock.
Separately, Zacks Investment Research lowered Zymeworks from a buy rating to a hold rating in a research note on Saturday, January 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $14.96.
Zymeworks stock opened at $12.18 on Monday. The company has a market capitalization of $314.45 and a PE ratio of -9.74. Zymeworks has a 12 month low of $6.25 and a 12 month high of $14.25.
ILLEGAL ACTIVITY NOTICE: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://stocknewstimes.com/2018/03/23/zymeworks-zyme-research-coverage-started-at-raymond-james-financial.html.
Zymeworks Inc is a Canada-based biopharmaceutical company. The Company specializes in the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The Company operates through a number of platforms, including Azymetric platform, which is developed for the development of IgG-like, novel bispecific antibodies for the targeting of synergistic drug targets; Albucore platform, which is developed as a flexible and alternative platform to antibodies where it is advantageous for multi-valent therapeutic to target multiple disease targets; Effect, which comprises a library of Fc modifications that can selectively modulate the activity of recruited immune cells, and the ZymeLink Conjugation platform, which is a suite of novel protein site-specific conjugation technologies and customizable cleavable and non-cleavable linkers that is compatible with a variety of small molecule therapeutics.
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.